JP2021531764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021531764A5 JP2021531764A5 JP2021502881A JP2021502881A JP2021531764A5 JP 2021531764 A5 JP2021531764 A5 JP 2021531764A5 JP 2021502881 A JP2021502881 A JP 2021502881A JP 2021502881 A JP2021502881 A JP 2021502881A JP 2021531764 A5 JP2021531764 A5 JP 2021531764A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- isolated antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 206
- 239000005557 antagonist Substances 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 7
- 102100035488 Nectin-2 Human genes 0.000 claims description 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 7
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 7
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 claims description 6
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 5
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 5
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 4
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 4
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 4
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 4
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 3
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 3
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 claims description 3
- 108010066979 Interleukin-27 Proteins 0.000 claims description 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 3
- 102100031789 Myeloid-derived growth factor Human genes 0.000 claims description 3
- 101150065403 NECTIN2 gene Proteins 0.000 claims description 3
- 102000002356 Nectin Human genes 0.000 claims description 3
- 108060005251 Nectin Proteins 0.000 claims description 3
- 102100035487 Nectin-3 Human genes 0.000 claims description 3
- 102100035486 Nectin-4 Human genes 0.000 claims description 3
- 108091059809 PVRL4 Proteins 0.000 claims description 3
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 3
- 229940044665 STING agonist Drugs 0.000 claims description 3
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 102000045804 human PVRIG Human genes 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 108010048507 poliovirus receptor Proteins 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 31
- 206010028980 Neoplasm Diseases 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 230000006051 NK cell activation Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000014828 interferon-gamma production Effects 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 208000026900 bile duct neoplasm Diseases 0.000 description 2
- 201000000053 blastoma Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 201000008184 embryoma Diseases 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 2
- 230000003571 opsonizing effect Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 201000002628 peritoneum cancer Diseases 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 210000004500 stellate cell Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229940119179 CD96 antagonist Drugs 0.000 description 1
- 206010025654 Malignant melanoma of sites other than skin Diseases 0.000 description 1
- 201000007552 Pituitary carcinoma Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229940123803 TIM3 antagonist Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- -1 or TIM-3 antagonist Proteins 0.000 description 1
- 208000011866 pituitary adenocarcinoma Diseases 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022023855A JP7633193B2 (ja) | 2018-07-20 | 2022-02-18 | 抗ｃｄ１１２ｒ組成物及び方法 |
| JP2024091126A JP7738129B2 (ja) | 2018-07-20 | 2024-06-05 | 抗ｃｄ１１２ｒ組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701065P | 2018-07-20 | 2018-07-20 | |
| US62/701,065 | 2018-07-20 | ||
| US201962844958P | 2019-05-08 | 2019-05-08 | |
| US62/844,958 | 2019-05-08 | ||
| PCT/US2019/042545 WO2020018879A1 (en) | 2018-07-20 | 2019-07-19 | Anti-cd112r compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023855A Division JP7633193B2 (ja) | 2018-07-20 | 2022-02-18 | 抗ｃｄ１１２ｒ組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531764A JP2021531764A (ja) | 2021-11-25 |
| JP2021531764A5 true JP2021531764A5 (https=) | 2022-01-06 |
| JP7072715B2 JP7072715B2 (ja) | 2022-05-20 |
Family
ID=69164765
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502881A Active JP7072715B2 (ja) | 2018-07-20 | 2019-07-19 | 抗ｃｄ１１２ｒ組成物及び方法 |
| JP2022023855A Active JP7633193B2 (ja) | 2018-07-20 | 2022-02-18 | 抗ｃｄ１１２ｒ組成物及び方法 |
| JP2024091126A Active JP7738129B2 (ja) | 2018-07-20 | 2024-06-05 | 抗ｃｄ１１２ｒ組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023855A Active JP7633193B2 (ja) | 2018-07-20 | 2022-02-18 | 抗ｃｄ１１２ｒ組成物及び方法 |
| JP2024091126A Active JP7738129B2 (ja) | 2018-07-20 | 2024-06-05 | 抗ｃｄ１１２ｒ組成物及び方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US11279758B2 (https=) |
| EP (1) | EP3823673A4 (https=) |
| JP (3) | JP7072715B2 (https=) |
| KR (1) | KR20210032488A (https=) |
| CN (1) | CN112584865A (https=) |
| AU (1) | AU2019306628B2 (https=) |
| BR (1) | BR112021000727A2 (https=) |
| CA (1) | CA3106114A1 (https=) |
| CL (1) | CL2021000149A1 (https=) |
| CO (1) | CO2021001912A2 (https=) |
| IL (1) | IL280134A (https=) |
| MX (2) | MX2021000745A (https=) |
| MY (1) | MY204773A (https=) |
| PH (1) | PH12021550152A1 (https=) |
| SG (1) | SG11202100373VA (https=) |
| TW (1) | TWI841577B (https=) |
| WO (1) | WO2020018879A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021000727A2 (pt) * | 2018-07-20 | 2021-04-13 | Surface Oncology, Inc. | Composições anti-cd112r e métodos |
| BR112022009405A2 (pt) * | 2019-11-15 | 2022-08-09 | Surface Oncology Inc | Composições e métodos para imunoterapia |
| WO2021113831A1 (en) | 2019-12-05 | 2021-06-10 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
| TW202216778A (zh) * | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022165275A2 (en) | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies |
| EP4284516A1 (en) | 2021-01-28 | 2023-12-06 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
| EP4292611A4 (en) * | 2021-02-09 | 2025-06-25 | Shanghai Junshi Biosciences Co., Ltd. | ANTI-CD112R ANTIBODIES AND USE THEREOF |
| US20240270840A1 (en) * | 2021-02-11 | 2024-08-15 | Nectin Therapeutics Ltd. | Antibodies against cd112r and uses thereof |
| JP2024511831A (ja) | 2021-03-31 | 2024-03-15 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 抗原結合タンパク質およびそれらの組み合わせ |
| AU2022320667A1 (en) * | 2021-07-30 | 2024-03-14 | Shandong Simcere Biopharmaceutical Co., Ltd. | Anti-pvrig/anti-tigit bispecific antibody and application |
| JP2024535793A (ja) | 2021-09-15 | 2024-10-02 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｐｄ－１に特異的に結合するタンパク質及びその医薬的使用 |
| PE20251671A1 (es) | 2022-03-15 | 2025-06-30 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer |
| CN116925233A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 |
| CN116925222A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗pvrig抗体、其药物组合物及用途 |
| US20260035460A1 (en) | 2022-07-28 | 2026-02-05 | Adeboye Henry ADEWOYE, MD | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
| CN119630423A (zh) * | 2022-08-05 | 2025-03-14 | 上海君实生物医药科技股份有限公司 | 抗cd112r抗体药物组合物及其用途 |
| JP2025529238A (ja) * | 2022-08-31 | 2025-09-04 | 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 | 抗ｐｖｒｉｇ抗体及びその使用 |
| WO2024098980A1 (en) * | 2022-11-10 | 2024-05-16 | Huahui Health Ltd. | Anti-cd112r antibodies and use thereof |
| WO2024140031A1 (zh) * | 2022-12-30 | 2024-07-04 | 杭州中美华东制药有限公司 | 一种靶向cd112r的抗体或其抗原结合片段及其应用 |
| CN120693178A (zh) | 2023-03-15 | 2025-09-23 | 上海迈晋生物医药科技有限公司 | 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途 |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP1210424B1 (en) | 1999-08-23 | 2007-02-07 | Dana-Farber Cancer Institute, Inc. | Novel b7-4 molecules and uses therefor |
| CN100427603C (zh) | 1999-10-04 | 2008-10-22 | 麦迪卡格公司 | 调控外源基因转录的方法 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| EP1256348B1 (en) * | 2000-02-14 | 2012-05-02 | Mitsubishi Tanabe Pharma Corporation | Remedies for hepatitis c |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| AU2003290432A1 (en) | 2002-12-26 | 2004-07-22 | Asahi Kasei Pharma Corporation | T cell activating gene |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| CA2561947A1 (en) | 2004-04-09 | 2005-10-20 | Takeda Pharmaceutical Company Limited | Preventives/remedies for cancer |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2588613C (en) | 2004-11-23 | 2010-09-14 | Pip Co., Ltd. | Built-in wall water service box |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US20070036786A1 (en) | 2005-07-11 | 2007-02-15 | Nadine Tuaillon | Method of treating autoimmune disease using humanized anti-CD16A antibodies |
| US7842466B1 (en) | 2005-09-16 | 2010-11-30 | Celera Corporation | Colon disease targets and uses thereof |
| WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| CA2666249A1 (en) | 2006-10-06 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Agent for preventing/treating cancer |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| TW201019959A (en) | 2008-08-19 | 2010-06-01 | Regeneron Pharma | Human antibodies to human RANKL |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| US20110007023A1 (en) | 2009-07-09 | 2011-01-13 | Sony Ericsson Mobile Communications Ab | Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| DK2593594T3 (en) | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| US20140141996A1 (en) | 2011-06-22 | 2014-05-22 | Oncocyte Corporation | Methods and Compositions for the Treatment and Diagnosis of Cancer |
| EP2768858B1 (en) * | 2011-10-18 | 2018-08-01 | Emory University | Antibodies directed against influenza |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| MX2014014951A (es) | 2012-06-06 | 2015-03-13 | Oncomed Pharm Inc | Agentes aglutinantes que modulan la trayectoria hippo y sus usos. |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| HK1210964A1 (en) | 2012-12-04 | 2016-05-13 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| SG11201700258VA (en) | 2014-07-16 | 2017-02-27 | Genentech Inc | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| US10227408B2 (en) | 2015-02-19 | 2019-03-12 | Compugen Ltd. | Anti-PVRIG antibodies and methods of use |
| EP3344657A1 (en) * | 2015-09-02 | 2018-07-11 | The Regents of the University of Colorado, A Body Corporate | Compositions and methods for modulating t-cell mediated immune response |
| CA2997444A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| WO2017221255A1 (en) | 2016-06-23 | 2017-12-28 | Memed Diagnostics Ltd. | Measuring trail by lateral flow immunoassay |
| WO2018017864A2 (en) * | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
| CN110088132B (zh) | 2016-08-17 | 2020-10-27 | 康姆普根有限公司 | 抗tigit抗体，抗pvrig抗体及其组合 |
| CA3101019A1 (en) | 2018-06-01 | 2019-12-05 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
| BR112021000727A2 (pt) | 2018-07-20 | 2021-04-13 | Surface Oncology, Inc. | Composições anti-cd112r e métodos |
-
2019
- 2019-07-19 BR BR112021000727-0A patent/BR112021000727A2/pt unknown
- 2019-07-19 SG SG11202100373VA patent/SG11202100373VA/en unknown
- 2019-07-19 MY MYPI2021000280A patent/MY204773A/en unknown
- 2019-07-19 EP EP19838134.5A patent/EP3823673A4/en active Pending
- 2019-07-19 WO PCT/US2019/042545 patent/WO2020018879A1/en not_active Ceased
- 2019-07-19 CN CN201980048428.4A patent/CN112584865A/zh active Pending
- 2019-07-19 KR KR1020217004824A patent/KR20210032488A/ko active Pending
- 2019-07-19 TW TW108125739A patent/TWI841577B/zh active
- 2019-07-19 CA CA3106114A patent/CA3106114A1/en active Pending
- 2019-07-19 MX MX2021000745A patent/MX2021000745A/es unknown
- 2019-07-19 AU AU2019306628A patent/AU2019306628B2/en active Active
- 2019-07-19 JP JP2021502881A patent/JP7072715B2/ja active Active
- 2019-07-19 US US16/516,613 patent/US11279758B2/en active Active
- 2019-07-19 US US17/261,463 patent/US11214619B2/en active Active
-
2021
- 2021-01-12 IL IL280134A patent/IL280134A/en unknown
- 2021-01-19 MX MX2025011666A patent/MX2025011666A/es unknown
- 2021-01-19 CL CL2021000149A patent/CL2021000149A1/es unknown
- 2021-01-19 PH PH12021550152A patent/PH12021550152A1/en unknown
- 2021-02-17 CO CONC2021/0001912A patent/CO2021001912A2/es unknown
- 2021-11-19 US US17/531,380 patent/US12162941B2/en active Active
-
2022
- 2022-02-18 JP JP2022023855A patent/JP7633193B2/ja active Active
-
2024
- 2024-06-05 JP JP2024091126A patent/JP7738129B2/ja active Active
- 2024-10-29 US US18/930,273 patent/US20250051449A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021531764A5 (https=) | ||
| WO2020018879A4 (en) | Anti-cd112r compositions and methods | |
| JP7671377B2 (ja) | 抗メソテリン抗体 | |
| JP2020501531A5 (https=) | ||
| EP3334431B9 (en) | 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| JP2021518103A5 (https=) | ||
| CN113302207B (zh) | Cd38和icam1抗体及其用途 | |
| JP2020103301A5 (https=) | ||
| JP2021524249A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| JP2020534250A5 (https=) | ||
| JP2020507571A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2019500891A5 (https=) | ||
| JP2019500892A5 (https=) | ||
| JP2017506067A5 (https=) | ||
| JP2020512281A5 (https=) | ||
| CN111886255B (zh) | 抗tim3抗体及其用途 | |
| JP2020515247A5 (https=) | ||
| JP2018501211A5 (https=) | ||
| EP4001308A1 (en) | Anti-tigit antibodies and application thereof | |
| WO2023040945A1 (zh) | 特异性结合pd-1的蛋白及其医药用途 | |
| JP2020515577A5 (https=) | ||
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| CN115197325A (zh) | 抗体在抗肿瘤治疗中的用途 |